Bankruptcy threat looms as Quince runs out of options
Investor panic has poleaxed Quince Therapeutics share price, after a regulatory filing revealed the biotech's cash is running out.
Newsletters and Deep Dive digital magazine
Investor panic has poleaxed Quince Therapeutics share price, after a regulatory filing revealed the biotech's cash is running out.
Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.
This week's biofinancings include a nine-figure round for ILiAD, with Quantx Bio, Aerska, Galux, and Pandorum Technologies also raising new funds.
Shares in BridgeBio rose after it revealed data from a trial of infigratinib in achondroplasia, raising the prospect of the first oral treatment.
Major venture capital groups in Europe have joined forces to set up a new coalition aimed at revitalising access to life sciences investment.
Editor's Picks
Newsletters and Deep Dive
digital magazine